News archive
Showing 771 results
May 2026
-
Story Education and Awareness
A Conversation Women Wish They’d Had: Understanding the Risk of Breast Cancer Coming Back
Findings from the Breast Health & Experience Index reveal many women diagnosed with breast cancer want earlier, more honest conversations about the possibility of recurrence to help them feel more informed and empowered.
-
Media Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…
April 2026
-
Media Release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North… -
Media Release
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded… -
Media Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…
March 2026
-
Story Hope
The Future of Treating Autoimmune Diseases: Science, Tech, & Patients Driving Progress
Today, 1 in 10 people in the United States have an autoimmune disease. Scientific innovations are opening pathways to help more patients.
-
Media Release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1… -
Story Education and Awareness
Susan’s Story: I Never Imagined I’d Be Someone Who Had a Heart Attack
For Susan, having two heart attacks in the span of a year was a wake-up call. It led her to be tested for high lipoprotein (a), a hidden heart disease risk factor that approximately 1 in 5 Americans may have1.
-
Media Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx® data build on extensive body of… -
Media Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL‑17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty,… -
Story Education and Awareness
"Could We End Preventable Heart Disease in Our Lifetime?" Novartis leaders explore at TIME100 Health event
If we look beyond the latest health trends, a healthy heart is the true key to more life in every year. Novartis US President Victor Bultó explains why preventing cardiovascular disease is the longevity breakthrough that matters.
-
Story Education and Awareness
Five Questions with Des Creary, Novartis US Chief Customer Engagement Officer
In this interview, Des shares his perspective on why it is important we work to better support healthcare practitioners who help treat our patients, and why real innovation resides in people as much as it resides in products.